<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10188891</article-id><article-id pub-id-type="pmc">2362741</article-id><article-id pub-id-type="pii">6690233</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690233</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Negoro</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kudoh</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Okishio</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Takada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff3">4</xref></contrib><contrib contrib-type="author"><name><surname>Tada</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff5">6</xref></contrib><contrib contrib-type="author"><name><surname>Fukuoka</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><aff id="aff1">Department of Pulmonary Medicine, Department of Radiology,Osaka City General Hospital, 2-13-22, Osaka, Miyakojima-ku, 534-0021, Japan</aff><aff id="aff3">First Department of Internal Medicine, First Department of Radiology, Osaka City University School of Medicine, 1-5-7, Osaka, Abeno-ku, 545-0051, Japan</aff><aff id="aff5">Second Department of Internal Medicine,Department of Radiology, Osaka Prefectural Habikino Hospital, 3-7-1, Osaka, Habikino, 583-0872, Japan</aff><aff id="aff7">Fourth Department of Internal Medicine, Kinki University, School of Medicine, Osaka-Sayama, Ohnohigashi, 589-0014, Japan</aff></contrib-group><pub-date pub-type="ppub"><month>3</month><year>1999</year></pub-date><volume>79</volume><issue>9-10</issue><fpage>1462</fpage><lpage>1467</lpage><history><date date-type="received"><day>19</day><month>05</month><year>1998</year></date><date date-type="rev-recd"><day>18</day><month>09</month><year>1998</year></date><date date-type="accepted"><day>14</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan administered weekly with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. In a phase I/II clinical trial, patients with histologically documented, surgically unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC) were enrolled. Irinotecan was administered as a 90 min intravenous infusion once weekly for 6 weeks. The starting dose was 30 mg m<sup>&#x02212;2</sup> and dose escalation was done in 15 mg m<sup>&#x02212;2</sup> increments. Dose-limiting toxicity was defined as grade 3 nonhaematologic toxicity (excluding nausea, vomiting and alopecia) or grade 4 haematologic toxicity according to the WHO criteria. Radiation was delivered to the primary tumour and regional lymph nodes (40 Gy), followed by a boost to the primary tumour (20 Gy). Twenty-seven patients were entered into this study at three irinotecan dose levels (30, 45 and 60 mg m<sup>&#x02212;2</sup>). Twenty-six eligible patients were evaluated for toxic effects and clinical outcome. Severe oesophagitis, pneumonitis, and diarrhoea occurred at 45 and 60 mg m<sup>&#x02212;2</sup>. Three of the five patients given 60 mg m<sup>&#x02212;2</sup> developed grade 3 or 4 oesophagitis and pneumonitis. In addition, one patient died of pneumonitis after completing therapy at 45 mg m<sup>&#x02212;2</sup> in the phase II study. The objective response rate was 76.9&#x00025; (95&#x00025; CI, 53.0&#x02013;88.9&#x00025;). Oesophagitis, pneumonitis, and diarrhoea are the dose-limiting toxicities of weekly irinotecan combined with thoracic irradiation. The maximum tolerated dose and the dose for the phase II study were 60 and 45 mg m<sup>&#x02212;2</sup> wk<sup>&#x02212;1</sup>, respectively. This combined therapy for locally advanced non-small cell lung cancer is promising and shows acceptable toxicity. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>irinotecan</kwd><kwd>chemoradiotherapy</kwd><kwd>clinical trial</kwd><kwd>radiosensitization</kwd></kwd-group></article-meta></front></article>
